Cubist Pharmaceuticals Inc. (CBST) announced positive results from its Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections Monday morning. Ceftolozane/tazobactam met its primary endpoint of statistical non-inferiority compared to levofloxacin.
Cubist Pharmaceuticals gapped open sharply higher Monday morning and is now up 3.43 at $68.93. The stock has risen above nearly a 4-month range and has set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News